D10.1 Quality assurance guidelines and procedures
12 July 2022
Outcomes
D10.4 Data Management plan for RBDCOV project
11 February 2022
D8.1 Project Website
17 March 2022
D8.3 Report on communication and dissemination activities
7 December 2022
Press Office
Susana Garayoa sgarayoa@zabala.eu
Phone number: M (+32) 484 61 91 64
(Brussels)
Nora Franco: nfranco@zabala.es
Phone number: M (+34) 673 005 759
(Pamplona)
Publications
Humoral immunity after PHH-1V COVID-19 booster vaccination
22 May 2025
Individuals with immunosuppressive conditions are at high risk of developing SARS-CoV-2–associated complications and face death, and their responses to vaccination widely vary upon the underlying immune impairment.
Studying humoral and cellular responses of RBD, receptor bindingdomain, based Covid-19 vaccine
28 May 2025
Studying humoral and cellular responses of RBD, receptor binding domain, based Covid-19 vaccine.
